Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | CBFB | Q13951 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503265 | 1.00 | CCR1 (0.35) | CCR1CCR5CCR8APLNRMAPK14 | |
| SCHEMBL2296011 | 0.94 | CCR1 (0.35) | CCR1CCR5CCR8APLNRMAPK14 | |
| SCHEMBL2299762 | 0.87 | — | — | |
| SCHEMBL2297367 | 0.87 | RECQL (0.32) | — | |
| SCHEMBL2299388 | 0.86 | TSHR (0.32) | TSHR | |
| SCHEMBL2300658 | 0.84 | TRPV3 (0.33) | — | |
| SCHEMBL2298225 | 0.84 | TRPV3 (0.33) | — | |
| SCHEMBL2295328 | 0.83 | — | — | |
| SCHEMBL16496400 | 0.82 | USP7 (0.35) | — | |
| SCHEMBL3394974 | 0.82 | USP7 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2244711-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Incorporated (US) | 2010-11-03 | — | — | EP | claimed |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED | 2009-10-08 | — | — | US | claimed |
| WO-2009099594-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-08-13 | — | — | WO | claimed |
| US-7989469-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TNNC1, TNNI3, TNNT2 | CCR1 1960/4885CCR5 1538/4885CCR8 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.